Microbiotica’s timeline
2024
Microbiotica Announces First Patient Dosed in its Phase 1b Trial
Careers | Find us | Contact us
Microbiotica’s timeline
2025-04-29T14:16:06+01:0029 April 2025|
Microbiotica Announces First Patient Dosed in its Phase 1b Trial
2025-04-29T14:16:51+01:0029 April 2025|
Microbiotica Announces First Patient Dosed in its International Phase 1b
2025-04-29T14:17:06+01:0029 April 2025|
Microbiotica’s Microbiome Medicines in Melanoma and Ulcerative Colitis Gain Regulatory
2025-04-29T14:17:26+01:0029 April 2025|
Microbiotica announces transition of leadership, with Mark Romanos stepping down
2025-04-29T14:17:34+01:0029 April 2025|
Microbiotica wins the Business Weekly Life Science Innovation award and
2025-04-29T14:17:41+01:0029 April 2025|
Microbiotica raises £50 million ($67 million) to advance the pipeline
2025-04-29T14:17:54+01:0029 April 2025|
Microbiotica assets MB097 and MB310 achieve preclinical proof of concept
2025-04-29T14:18:10+01:0029 April 2025|
Microbiotica signs strategic collaboration in Immuno-oncology with Cancer Research UK
2025-04-29T14:18:19+01:0029 April 2025|
Microbiotica’s Co-founder Professor Gordon Dougan receives the 2020 Albert B.
Wellcome Genome Campus,
Hinxton, Cambridgeshire,
CB10 1SA. UK
+44 (0)1223 834244


Wellcome Genome Campus,
Hinxton, Cambridgeshire, CB10 1SA. UK
+44 (0)1223 834244

